Ardaman Shergill to Kaplan-Meier Estimate
This is a "connection" page, showing publications Ardaman Shergill has written about Kaplan-Meier Estimate.
Connection Strength
0.077
-
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.
Score: 0.050
-
Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2016 Jun; 16(6):350-7.
Score: 0.028